Mergers and Acquisitions in the Pharmaceutical Sector Since the Last 10years to Cope with the Mutations of This Sector.

Only available on StudyMode
  • Download(s) : 74
  • Published : May 20, 2012
Open Document
Text Preview
Mergers and acquisitions in the pharmaceutical sector since the last 10years to cope with the mutations of this sector.

[pic]

Contents

Title p.1

Introduction p.3

1. The pharmaceutical sector p.6

1.1. Introduction of the pharmaceutical sector
1.2 The actual pharmaceutical market
1.3 The actors of the pharmaceutical market
1.4 The strategic segmentation of the pharmaceutical market

2. The strict rules of the pharmaceutical sector in the world. p.12

2.1 Who runs the pharmaceutical industry ?
2.2. Why merging ?

3. Mergers in the market p.14

3.1 Different types of mergers in the pharmaceutical industry 3.2 Mergers and acquisitions process
3.3 Main strategic reasons
a) Financial reasons
b) Offensive reasons
c) Defensive reasons
d) Other reasons

4. The example of Pfizer’s take-over on Wyeth p.19

Conclusion p20

Referencesp23

During the first two years of my studies, the international marketing file represents a determining exercise of our business training. Indeed, this dissertation takes the form of a global report of our theoretical knowledge and techniques. Through this internal audit, we have the opportunity to use our capacities to analyse the world of this sector, its working policies and its stakes.

Within the framework of this file, my attention went on a powerful sector of the worldwide economy, but which is not a very recurring sector in the exercises of analysis of our training: the pharmaceutical industry.

This area seems worthy review because this sector is under-research every year in many countries, for example there are research by Joel Lexchin, associate professor School of Health Policy and Management, York University, Toronto ( Drugs of Choice: A Formulary for General Practice), Lisa A Bero, professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California at San Francisco(Financial Ties and Conflicts of Interest Between Pharmaceutical and Tobacco Companies. Journal of the American Medical Association, 2002), Benjamin Djulbegovic, associate professor Interdisciplinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa. (Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers, 2008), William Comanor, professor of Public Policy and Corporate Management in the Aetna Chair, Emeritus, Harvard Kennedy School, University of California, “Mergers and Innovation in the Pharmaceutical Market” (2011).

During second half of the 20th century, the largest world pharmaceutical firms strongly developed, benefitting from a simple report: in the course of time, the human placed health at the top of his concerns.

Pushed by the world economic growth and the progressive globalization of exchanges, the pharmaceutical laboratories became important, financially powerful economic agents, and profiting from a worldwide presence. Today, this sector represents “more than 700 billion dollars, and its actors are, mainly, quoted on the Stock Exchange market” (Bailey, R. 2011)

However, the market of drugs and medical care is a difficult one. The insane growth of the Eighties and Nineties left the place to a fierce competition between the firms of the sector.

Our interest for this subject comes up to the fact that this end of the decade 2000 announces an historical turning point in the pharmaceutical market evolution. “The...
tracking img